Greenland Capital Management LP Invests $2.13 Million in Abivax SA Sponsored ADR $ABVX

Greenland Capital Management LP purchased a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the third quarter, Holdings Channel reports. The firm purchased 25,039 shares of the company’s stock, valued at approximately $2,126,000.

Other large investors have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its holdings in Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company’s stock worth $32,000 after purchasing an additional 369 shares during the period. First Horizon Corp bought a new position in shares of Abivax in the 3rd quarter worth about $36,000. Bank of America Corp DE boosted its holdings in shares of Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after buying an additional 1,990 shares during the period. Hantz Financial Services Inc. acquired a new position in shares of Abivax in the 3rd quarter valued at about $52,000. Finally, Cubist Systematic Strategies LLC grew its position in shares of Abivax by 34.3% during the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after buying an additional 2,595 shares during the last quarter. 47.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on ABVX shares. Morgan Stanley raised their target price on shares of Abivax from $101.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, January 9th. Citigroup reissued a “market outperform” rating on shares of Abivax in a report on Thursday, January 8th. Wedbush began coverage on Abivax in a research report on Tuesday. They set an “underperform” rating for the company. Wall Street Zen lowered Abivax from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th. Finally, Wolfe Research upgraded Abivax to a “strong-buy” rating in a research note on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $137.00.

Abivax Stock Performance

Shares of ABVX stock opened at $132.91 on Tuesday. Abivax SA Sponsored ADR has a 12-month low of $4.77 and a 12-month high of $148.83. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.86 and a quick ratio of 7.86. The firm has a market capitalization of $10.51 billion, a price-to-earnings ratio of -31.80 and a beta of 0.81. The business has a 50 day simple moving average of $123.45 and a 200 day simple moving average of $104.84.

Abivax (NASDAQ:ABVX) last announced its earnings results on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The business had revenue of ($4.92) million during the quarter. On average, equities research analysts anticipate that Abivax SA Sponsored ADR will post -2.83 EPS for the current year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.